Check Out What’s New at Goldfinch

08.02.22

Goldfinch Bio to Present at the 2022 Wedbush PacGrow Healthcare Virtual Conference

07.07.22

Goldfinch Bio Announces Publication in Science Advances on the Validation of Human Derived Organoids as a Predictable and Translatable Preclinical Model in Kidney Disease for the Evaluation of Therapeutic Drug Candidates

05.31.22

Goldfinch Bio to Present Initial Data from Phase 1 Clinical Trial of GFB-024 at American Diabetes Association 82nd Scientific Sessions and Endocrine Society’s Annual Meeting, ENDO 2022

03.22.22

Goldfinch Bio to Host Virtual Event on Unmet Need in Focal Segmental Glomerulosclerosis (FSGS) and GFB-887 as a Novel Kidney Precision Medicine Candidate

02.28.22

Goldfinch Bio Announces Positive Preliminary Data from Phase 2 Clinical Trial Evaluating GFB-887 as a Precision Medicine for Patients with Focal Segmental Glomerular Sclerosis (FSGS)